Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 6/20 | 0.54 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | F10 | P00742 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824303 | 0.80 | CA1 (0.67) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| P-Anisic Acid SCHEMBL27338972 | 0.78 | CA1 (0.95) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4478523 | 0.77 | MEN1 (0.54) | RAB9ANPC1SMN1; SMN2GAAALDH1A1 | |
| SCHEMBL5442673 | 0.76 | CA1 (0.77) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| P-Anisic Acid SCHEMBL1157044 | 0.76 | CA1 (1.00) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| P-Anisic Acid SCHEMBL43335 | 0.76 | CA1 (1.00) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11729306 | 0.75 | RAB9A (0.86) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| P-Anisic Acid SCHEMBL27622882 | 0.75 | CA1 (0.69) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL8353010 | 0.75 | CA1 (0.74) | CA1CA2RAB9ANPC1SMN1; SMN2 | |
| Terephthalic Acid SCHEMBL8989156 | 0.75 | CA1 (0.74) | CA1CA2RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1622572-B1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS INC (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3231445-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-10-18 | — | — | EP | disclosed |
| EP-3222294-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | Sirna Therapeutics, Inc. (US) | 2017-09-27 | — | — | EP | disclosed |
| EP-2415486-B1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS INC (US) | 2017-02-22 | — | — | EP | disclosed |
| US-8461313-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| US-20120202983-A1 | Conjugates and Compositions for Cellular Delivery | SIRNA THERAPEUTICS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8188247-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2012-05-29 | — | — | US | disclosed |
| EP-2415486-A2 | Conjugates and compositions for cellular delivery | Sirna Therapeutics, Inc. (US) | 2012-02-08 | — | — | EP | disclosed |
| US-7964578-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | CHEN TONGQIAN | 2011-05-26 | — | — | US | disclosed |
| US-20100331535-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | MATULIC-ADAMIC JASENKA | 2010-12-30 | — | — | US | disclosed |
| US-7858625-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2010-12-28 | — | — | US | disclosed |
| US-7833992-B2 | biological conjugates used for drug delivery; side effect reduction | MERCK SHARPE & DOHME (US) | 2010-11-16 | — | — | US | disclosed |
| US-20090264636-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | SIRNA THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | US | disclosed |
| US-7491805-B2 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-7109165-B2 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20050239739-A1 | Conjugates and compositions for cellular delivery | SIRNA THERAPEUTICS, INC. | 2005-10-27 | — | — | US | disclosed |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | SIRNA THERAPEUTICS, INC. (US) | 2004-12-09 | — | — | US | disclosed |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | RIBOZYME PHARMACEUTICALS, INC. | 2004-06-10 | — | — | US | disclosed |
| US-20030104985-A1 | Conjugates and compositions for cellular delivery | BANK OF AMERICA, N.A. | 2003-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239739-A1 | Conjugates and compositions for cellular delivery | MTHFD1, FOLR1, FOLR2 | CA1 1594/4885CA2 2395/4885RAB9A 3177/4885 |
| US-20110124853-A1 | Conjugates and Compositions for Cellular Delivery | ALB, PHAX, HEXA | CA1 1903/4885CA2 3820/4885RAB9A 2898/4885 |
| US-20030104985-A1 | Conjugates and compositions for cellular delivery | MTHFD1, FOLR1, FOLR2 | CA1 1594/4885CA2 2395/4885RAB9A 3177/4885 |
| US-20120202983-A1 | Conjugates and Compositions for Cellular Delivery | MTHFD1, FOLR1, FOLR2 | CA1 1594/4885CA2 2395/4885RAB9A 3177/4885 |
| US-20090264636-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | ALB, PHAX, HEXA | CA1 1903/4885CA2 3820/4885RAB9A 2898/4885 |
| US-20100331535-A1 | CONJUGATES AND COMPOSITIONS FOR CELLULAR DELIVERY | MTHFD1, FOLR1, FOLR2 | CA1 1594/4885CA2 2395/4885RAB9A 3177/4885 |
| US-20040249178-A1 | Biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | CA1 2054/4885CA2 3528/4885RAB9A 2851/4885 |
| US-20040110296-A1 | biological conjugates used for drug delivery; side effect reduction | ALB, HEXA, ADAR | CA1 2054/4885CA2 3528/4885RAB9A 2851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.